PUMA BIOTECHNOLOGY INC's ticker is PBYI and the CUSIP is 74587V107. A total of 201 filers reported holding PUMA BIOTECHNOLOGY INC in Q1 2015. The put-call ratio across all filers is 0.90 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $653,904 | -72.6% | 200,584 | -55.5% | 0.00% | – |
Q1 2024 | $2,388,075 | +375.6% | 450,580 | +288.6% | 0.00% | – |
Q4 2023 | $502,085 | +126.9% | 115,955 | +37.8% | 0.00% | – |
Q3 2023 | $221,299 | -15.2% | 84,144 | +13.8% | 0.00% | – |
Q2 2023 | $260,916 | +14.1% | 73,914 | -0.1% | 0.00% | – |
Q1 2023 | $228,672 | -29.3% | 74,004 | -3.2% | 0.00% | – |
Q4 2022 | $323,388 | +113769.0% | 76,451 | -36.0% | 0.00% | – |
Q3 2022 | $284 | -54.8% | 119,532 | -45.9% | 0.00% | – |
Q2 2022 | $629 | -100.0% | 220,892 | -49.8% | 0.00% | – |
Q1 2022 | $1,267,000 | -81.7% | 439,834 | -80.7% | 0.00% | -100.0% |
Q4 2021 | $6,941,000 | +22.5% | 2,283,165 | +182.6% | 0.00% | 0.0% |
Q3 2021 | $5,664,000 | +59.6% | 807,926 | +109.0% | 0.00% | 0.0% |
Q2 2021 | $3,548,000 | -55.8% | 386,560 | -53.2% | 0.00% | -50.0% |
Q1 2021 | $8,024,000 | +12.1% | 825,462 | +18.3% | 0.00% | 0.0% |
Q4 2020 | $7,161,000 | -21.8% | 697,933 | -23.1% | 0.00% | -33.3% |
Q3 2020 | $9,153,000 | -10.9% | 907,080 | -7.9% | 0.00% | 0.0% |
Q2 2020 | $10,271,000 | +58.5% | 984,680 | +28.3% | 0.00% | +50.0% |
Q1 2020 | $6,480,000 | -3.6% | 767,753 | -0.0% | 0.00% | 0.0% |
Q4 2019 | $6,721,000 | -36.7% | 768,069 | -22.1% | 0.00% | -33.3% |
Q3 2019 | $10,614,000 | +60.3% | 985,982 | +89.3% | 0.00% | +50.0% |
Q2 2019 | $6,620,000 | -76.0% | 520,919 | -26.8% | 0.00% | -75.0% |
Q1 2019 | $27,622,000 | +292.9% | 712,101 | +106.1% | 0.01% | +300.0% |
Q4 2018 | $7,031,000 | -37.0% | 345,507 | +41.8% | 0.00% | -33.3% |
Q3 2018 | $11,168,000 | -20.7% | 243,575 | +2.2% | 0.00% | -25.0% |
Q2 2018 | $14,091,000 | +9.7% | 238,229 | +26.2% | 0.00% | +33.3% |
Q1 2018 | $12,844,000 | -76.0% | 188,746 | -65.1% | 0.00% | -76.9% |
Q4 2017 | $53,496,000 | -20.6% | 541,186 | -3.9% | 0.01% | -23.5% |
Q3 2017 | $67,414,000 | +57.9% | 562,954 | +15.2% | 0.02% | +54.5% |
Q2 2017 | $42,697,000 | +213.7% | 488,517 | +33.5% | 0.01% | +175.0% |
Q1 2017 | $13,611,000 | +153.0% | 365,881 | +108.8% | 0.00% | +100.0% |
Q4 2016 | $5,380,000 | -48.4% | 175,267 | +12.7% | 0.00% | -33.3% |
Q3 2016 | $10,426,000 | +161.7% | 155,496 | +16.3% | 0.00% | +200.0% |
Q2 2016 | $3,984,000 | -21.1% | 133,722 | -22.2% | 0.00% | -50.0% |
Q1 2016 | $5,048,000 | -85.7% | 171,873 | -61.9% | 0.00% | -81.8% |
Q4 2015 | $35,371,000 | +43.1% | 451,170 | +37.5% | 0.01% | +37.5% |
Q3 2015 | $24,724,000 | -19.2% | 328,080 | +25.2% | 0.01% | -20.0% |
Q2 2015 | $30,583,000 | -46.0% | 261,950 | +9.2% | 0.01% | -47.4% |
Q1 2015 | $56,632,000 | +668.3% | 239,852 | +515.9% | 0.02% | +533.3% |
Q4 2014 | $7,371,000 | -23.2% | 38,946 | -3.2% | 0.00% | 0.0% |
Q3 2014 | $9,603,000 | -9.5% | 40,250 | -75.0% | 0.00% | -25.0% |
Q2 2014 | $10,609,000 | +1474.0% | 160,742 | +2382.9% | 0.00% | – |
Q1 2014 | $674,000 | +129.3% | 6,474 | +127.9% | 0.00% | – |
Q4 2013 | $294,000 | -74.1% | 2,841 | -86.6% | 0.00% | – |
Q3 2013 | $1,137,000 | +151.5% | 21,198 | +108.2% | 0.00% | – |
Q2 2013 | $452,000 | – | 10,182 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Cormorant Asset Management, LP | 507,500 | $121,074,000 | 24.90% |
BB BIOTECH AG | 476,991 | $113,796,000 | 4.63% |
ADAGE CAPITAL PARTNERS GP, L.L.C. | 5,686,668 | $1,356,668,000 | 3.35% |
WEATHERBIE CAPITAL, LLC | 101,055 | $24,109,000 | 2.26% |
Avalon Global Asset Management LLC | 16,000 | $3,817,000 | 2.24% |
Redmile Group, LLC | 51,025 | $12,173,000 | 1.41% |
Fernwood Investment Management, LLC | 6,700 | $1,598,000 | 1.38% |
Iguana Healthcare Management, LLC | 10,000 | $2,386,000 | 1.27% |
LMR Partners LLP | 56,632 | $13,510,000 | 1.08% |
FRANKLIN STREET ADVISORS INC /NC | 21,990 | $5,246,000 | 1.00% |